PT2235007E - Antagonistas não esteróides do receptor de mineralocorticóides derivados de 6h-dibenzo[b,e]oxepina - Google Patents

Antagonistas não esteróides do receptor de mineralocorticóides derivados de 6h-dibenzo[b,e]oxepina

Info

Publication number
PT2235007E
PT2235007E PT88668355T PT08866835T PT2235007E PT 2235007 E PT2235007 E PT 2235007E PT 88668355 T PT88668355 T PT 88668355T PT 08866835 T PT08866835 T PT 08866835T PT 2235007 E PT2235007 E PT 2235007E
Authority
PT
Portugal
Prior art keywords
dibenz0
oxepine
receptor antagonists
mineralocorticoid receptor
derived
Prior art date
Application number
PT88668355T
Other languages
English (en)
Inventor
Konstantinos Gavardinas
Prabhakar Kondaji Jadhav
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40430143&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2235007(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PT2235007E publication Critical patent/PT2235007E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT88668355T 2007-12-19 2008-12-09 Antagonistas não esteróides do receptor de mineralocorticóides derivados de 6h-dibenzo[b,e]oxepina PT2235007E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1477607P 2007-12-19 2007-12-19

Publications (1)

Publication Number Publication Date
PT2235007E true PT2235007E (pt) 2013-01-22

Family

ID=40430143

Family Applications (1)

Application Number Title Priority Date Filing Date
PT88668355T PT2235007E (pt) 2007-12-19 2008-12-09 Antagonistas não esteróides do receptor de mineralocorticóides derivados de 6h-dibenzo[b,e]oxepina

Country Status (34)

Country Link
US (1) US7994164B2 (pt)
EP (2) EP2537845B1 (pt)
JP (1) JP5562866B2 (pt)
KR (1) KR101254382B1 (pt)
CN (1) CN101903377B (pt)
AR (1) AR069554A1 (pt)
AU (1) AU2008343524B2 (pt)
BR (1) BRPI0820805A2 (pt)
CA (1) CA2710409C (pt)
CL (1) CL2008003600A1 (pt)
CO (1) CO6300953A2 (pt)
DK (1) DK2235007T3 (pt)
DO (1) DOP2010000185A (pt)
EA (1) EA017668B1 (pt)
EC (2) ECSP10010266A (pt)
ES (2) ES2459318T3 (pt)
GT (1) GT201000179A (pt)
HK (1) HK1144284A1 (pt)
HR (1) HRP20120916T1 (pt)
IL (1) IL206353A (pt)
MA (1) MA31910B1 (pt)
MX (1) MX2010006911A (pt)
MY (1) MY150474A (pt)
NZ (1) NZ586300A (pt)
PE (1) PE20091057A1 (pt)
PL (1) PL2235007T3 (pt)
PT (1) PT2235007E (pt)
RS (1) RS52594B (pt)
SI (1) SI2235007T1 (pt)
TN (1) TN2010000292A1 (pt)
TW (1) TWI431010B (pt)
UA (1) UA100131C2 (pt)
WO (1) WO2009085584A1 (pt)
ZA (1) ZA201004257B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010535156A (ja) 2007-08-03 2010-11-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウイルスポリメラーゼ阻害剤
KR20100098534A (ko) 2007-12-19 2010-09-07 베링거 인겔하임 인터내셔날 게엠베하 바이러스 폴리머라제 억제제
KR101312179B1 (ko) * 2009-03-12 2013-09-26 일라이 릴리 앤드 캄파니 미네랄로코르티코이드 수용체 길항제 및 사용 방법
US8957052B2 (en) 2010-05-10 2015-02-17 Universite Paris Descartes Methods and compositions for the treatment of fluid accumulation in and/or under the retina
WO2011157798A1 (en) 2010-06-16 2011-12-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for stimulating reepithelialisation during wound healing
CN102060670A (zh) * 2011-01-04 2011-05-18 常州大学 一种2-溴-6-氟苯甲醇的制备方法
MD20150103A2 (ro) 2013-05-02 2016-02-29 Pfizer Inc. Derivaţi ai imidazo-triazinei ca inhibitori ai PDE10
AR099416A1 (es) 2014-02-28 2016-07-20 Lilly Co Eli Terapia combinada para la hipertensión resistente
WO2016001631A1 (en) 2014-06-30 2016-01-07 Astrazeneca Ab Benzoxazinone amides as mineralocorticoid receptor modulators
EA201790868A1 (ru) * 2014-11-21 2017-10-31 Эли Лилли Энд Компани 1,2-бензотиазольные соединения для лечения почечного расстройства
EP3362095B1 (en) 2015-10-13 2020-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
WO2018019843A1 (en) 2016-07-26 2018-02-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
MX2019003339A (es) * 2016-09-24 2019-06-03 Kbp Biosciences Co Ltd Composicion farmaceutica con antagonista del receptor de mineralocorticoides y su uso.
US20230151425A1 (en) 2020-03-11 2023-05-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of determining whether a subject has or is at risk of having a central serous chorioretinopathy
WO2023031277A1 (en) 2021-08-31 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of ocular rosacea

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4072756A (en) * 1973-05-17 1978-02-07 Sandoz Ltd. Tricyclo piperidino ketones and soporific compositions thereof
SE426341C (sv) * 1980-02-14 1985-09-23 Fagersta Ab Sett att forhindra korrosion i en forbrenningsanleggnings kylare och skorsten vid kylning av rokgaser
DE3730258A1 (de) * 1986-09-10 1988-04-07 Canon Kk Elektrophotographisches lichtempfindliches aufzeichnungsmaterial, 5h-dibenzo(a,d)cycloheptanylidenderivat, 5h-dibenzo(a,d)cycloheptenylidenderivat und verfahren zu ihrer herstellung
CA1338625C (en) * 1988-06-09 1996-10-01 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds
GB8914061D0 (en) * 1989-06-19 1989-08-09 Wellcome Found Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
US5378701A (en) * 1991-12-27 1995-01-03 Kyowa Hakko Kogyo Tricyclic compounds
AR014195A1 (es) 1997-12-29 2001-02-07 Ortho Mcneil Pharm Inc Compuestos de trifenilpropanamida utiles para el tratamiento de procesos inflamatorios, composiciones anti-inflamatorias que los comprenden, ymetodos para prepararlos
WO2000059884A1 (en) 1999-01-26 2000-10-12 Dana-Farber Cancer Institute, Inc. Pharmaceutically active compounds and methods of use thereof
PT1448566E (pt) * 2001-11-21 2006-08-31 Kyowa Hakko Kogyo Kk Antagonistas do receptor quimioquina e metodos de utilizacao do mesmo
TW200400816A (en) 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
WO2005066161A1 (en) * 2003-12-19 2005-07-21 Eli Lilly And Company Tricyclic steroid hormone nuclear receptor modulators
US7482344B2 (en) 2003-12-19 2009-01-27 Eli Lilly And Company Tricyclic steroid hormone nuclear receptor modulators
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
JP2008508314A (ja) * 2004-07-28 2008-03-21 アイアールエム・リミテッド・ライアビリティ・カンパニー ステロイドホルモン核内受容体のモジュレーターとしての化合物および組成物
TWI400239B (zh) 2004-11-10 2013-07-01 Incyte Corp 內醯胺化合物及其作為醫藥品之用途
RS20090208A (en) 2006-10-31 2010-06-30 Pfizer Products Inc. Pyrazoline compounds as mineralocorticoid receptor antagonists
US20100120736A1 (en) 2007-03-29 2010-05-13 N.V. Organon Mineralocorticoid Receptor Antagonists
GB0725102D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
PE20091339A1 (es) 2007-12-21 2009-09-26 Glaxo Group Ltd Derivados de oxadiazol con actividad sobre receptores s1p1
CA2711887A1 (en) 2008-01-25 2009-07-30 Arena Pharmaceuticals, Inc. Dihydro-1h-pyrrolo [1,2-a] indol-1-yl carboxylic derivatives which act as s1p1 agonists
KR101312179B1 (ko) 2009-03-12 2013-09-26 일라이 릴리 앤드 캄파니 미네랄로코르티코이드 수용체 길항제 및 사용 방법

Also Published As

Publication number Publication date
EA201070762A1 (ru) 2010-12-30
EP2537845A1 (en) 2012-12-26
ECSP12012048A (es) 2012-08-31
EA017668B1 (ru) 2013-02-28
NZ586300A (en) 2012-06-29
CN101903377B (zh) 2014-07-09
TW200930721A (en) 2009-07-16
US7994164B2 (en) 2011-08-09
CL2008003600A1 (es) 2010-02-19
MA31910B1 (fr) 2010-12-01
RS52594B (en) 2013-04-30
BRPI0820805A2 (pt) 2015-06-16
AU2008343524A1 (en) 2009-07-09
KR20100082866A (ko) 2010-07-20
TN2010000292A1 (en) 2011-11-11
JP5562866B2 (ja) 2014-07-30
HK1144284A1 (en) 2011-02-11
IL206353A (en) 2014-06-30
CA2710409C (en) 2012-11-06
EP2235007B1 (en) 2012-10-31
ES2459318T3 (es) 2014-05-09
US20090163472A1 (en) 2009-06-25
HRP20120916T1 (hr) 2012-12-31
WO2009085584A1 (en) 2009-07-09
IL206353A0 (en) 2010-12-30
TWI431010B (zh) 2014-03-21
SI2235007T1 (sl) 2013-01-31
EP2235007A1 (en) 2010-10-06
ES2396605T3 (es) 2013-02-22
MX2010006911A (es) 2010-10-05
PE20091057A1 (es) 2009-07-20
JP2011507868A (ja) 2011-03-10
MY150474A (en) 2014-01-30
PL2235007T3 (pl) 2013-03-29
DOP2010000185A (es) 2010-09-15
DK2235007T3 (da) 2012-12-17
CN101903377A (zh) 2010-12-01
KR101254382B1 (ko) 2013-04-15
AR069554A1 (es) 2010-02-03
ZA201004257B (en) 2011-11-30
CA2710409A1 (en) 2009-07-09
UA100131C2 (uk) 2012-11-26
CO6300953A2 (es) 2011-07-21
ECSP10010266A (es) 2010-07-30
AU2008343524B2 (en) 2012-03-08
EP2537845B1 (en) 2014-03-19
GT201000179A (es) 2012-04-16

Similar Documents

Publication Publication Date Title
HK1144284A1 (en) 6h-dibenz0 [b, e] oxepine derived nonsteroidal mineralocorticoid receptor antagonists
HRP20151108T1 (en) Nogo receptor antagonists
EP2184278A4 (en) P2X4 RECEIVER ANTAGONIST
EP2058304A4 (en) P2X4 RECEPTOR ANTAGONIST
EP2349270A4 (en) 2,5-DISUBSTITUTED MORPHOLINE OREXIN RECEPTOR ANTAGONISTS
EP2151236A4 (en) G PROTEIN COUPLED RECEPTOR AGONIST
EP2214676A4 (en) OXININE RECEPTOR ANTAGONISTS SUBSTITUTED DIAZEPAN TYPE
GB0509275D0 (en) Synthetic receptor
IL188478A0 (en) Indol-3-carbonyl-spiro-piperidine derivatives as v1a receptor antagonists
ZA200705449B (en) 2-phenyl-indoles as prostaglandin D2 receptor antagonists
IL196587A0 (en) 2-phenyl-indoles as prostaglandin d2 receptor antagonists
ZA200906812B (en) Crig antagonists
ZA201001125B (en) Pyrrolidine Aryl-Ether as NK3 receptor antagonists
ZA201000676B (en) Pyrrolidine aryl-ether as NK3 receptor antagonists
GB0717233D0 (en) Traffic monitoring
EP2191830A4 (en) SOLID PREPARATION COMPRISING A NPYY5 RECEPTOR ANTAGONIST
IL198542A0 (en) 2-aminoquinolines as 5-ht(5a)receptor antagonists
PT1912976E (pt) Derivados de indol-3-il-carboni-piperidin-benzimidazole como antagonistas dos receptores v1a
EP2153736A4 (en) NEW LEUKOTRIEN RECEPTOR ANTAGONIST
IL207700A0 (en) 3-aminoalkyl-1,4-diazepan-2-one melanocortin -5 receptor antagonists
EP2163557A4 (en) FUNCTIONAL DETECTIVE VITAMIN D RECEPTOR AGONISTS
IL207438A0 (en) 2-aminoquinolines as 5-ht5a receptor antagonists
IL211803A0 (en) Quinazoline derivatives as nk3 receptor antagonists
ZA200810564B (en) 2-phenyl-indoles as prostaglandin D2 receptor antagonists
GB0701632D0 (en) MET receptor antagonists